A live vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) developed using domestic technology is entering the global market.
BioPOA announced that "PoaVac PRRS Live Vaccine" is successfully exported to Thailand and Cambodia on February 4th and 18th.
The PoaVac PRRS Live Vaccine, developed through a joint research effort between the Animal and Plant Quarantine Agency and BioPOA, combines two North American strains of the PRRS virus, which were first identified in South Korea. It is applying the Reverse Genetics SAVE (Synthetic Attenuated Virus Engineering) leading technology.
The PoaVac PRRS Live Vaccine received domestic approval in 2021, and with the support of global animal health company CEVA Santé Animale, it also gained regulatory approval in both Cambodia and Thailand.
CEO Choi Sun-hee of BioPOA stated, "The PoaVac PRRS Live Vaccine was developed using the SAVE technology, specifically Codon Pair Deoptimization, which deliberately slows down the virus's replication speed. This results in a vaccine strain that is safe and has a heightened immune-inducing ability. As a result, it prevents excessive virus replication and potential side effects that can occur before immunity is triggered, while allowing enough time for the immune system to respond effectively."
He further emphasized, "The most notable feature of the PoaVac PRRS Live Vaccine is its ability to induce a strong cellular immune response through increased interferon-gamma. Additionally, there is minimal virus shedding, preventing the occurrence of circulating infections within farms."
CEO Choi continued, "Previous vaccines have shown cases where the virus was shed for extended periods from vaccinated pigs, or where the virus recombined with field strains, leading to increased virulence. The PoaVac PRRS Live Vaccine addresses these risks. Moreover, it has recently been approved for use in sows, enabling improvements in productivity not only in piglets but also in sows."
He added, "In addition to Southeast Asia, we are in the process of obtaining approvals to enter the Central and South American market. Starting with an export plan worth $1 million this year, we aim to significantly expand our market share both domestically and internationally within the next five years." He also mentioned, "BioPOA’s unique reverse genetics technology enables the rapid development of vaccine strains to respond to emerging viruses, allowing us to quickly release new products to counter mutant viruses. Through this, we will make our technological capabilities widely known in the global market."
A live vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) developed using domestic technology is entering the global market.
BioPOA announced that "PoaVac PRRS Live Vaccine" is successfully exported to Thailand and Cambodia on February 4th and 18th.
The PoaVac PRRS Live Vaccine, developed through a joint research effort between the Animal and Plant Quarantine Agency and BioPOA, combines two North American strains of the PRRS virus, which were first identified in South Korea. It is applying the Reverse Genetics SAVE (Synthetic Attenuated Virus Engineering) leading technology.
The PoaVac PRRS Live Vaccine received domestic approval in 2021, and with the support of global animal health company CEVA Santé Animale, it also gained regulatory approval in both Cambodia and Thailand.
CEO Choi Sun-hee of BioPOA stated, "The PoaVac PRRS Live Vaccine was developed using the SAVE technology, specifically Codon Pair Deoptimization, which deliberately slows down the virus's replication speed. This results in a vaccine strain that is safe and has a heightened immune-inducing ability. As a result, it prevents excessive virus replication and potential side effects that can occur before immunity is triggered, while allowing enough time for the immune system to respond effectively."
He further emphasized, "The most notable feature of the PoaVac PRRS Live Vaccine is its ability to induce a strong cellular immune response through increased interferon-gamma. Additionally, there is minimal virus shedding, preventing the occurrence of circulating infections within farms."
CEO Choi continued, "Previous vaccines have shown cases where the virus was shed for extended periods from vaccinated pigs, or where the virus recombined with field strains, leading to increased virulence. The PoaVac PRRS Live Vaccine addresses these risks. Moreover, it has recently been approved for use in sows, enabling improvements in productivity not only in piglets but also in sows."
He added, "In addition to Southeast Asia, we are in the process of obtaining approvals to enter the Central and South American market. Starting with an export plan worth $1 million this year, we aim to significantly expand our market share both domestically and internationally within the next five years." He also mentioned, "BioPOA’s unique reverse genetics technology enables the rapid development of vaccine strains to respond to emerging viruses, allowing us to quickly release new products to counter mutant viruses. Through this, we will make our technological capabilities widely known in the global market."